OS Therapies Inc(OSTX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
OSTX Stock Analysis & AI Quality Score
AI stock analysis and institutional research for OS Therapies Inc (OSTX), a Healthcare sector company. OSTX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), OS Therapies Inc reports net income of $-10.4M, free cash flow of $-4.6M. Top institutional holders of OSTX by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, SUSQUEHANNA INTERNATIONAL GROUP, LLP, CM Management,, based on the most recent SEC filings. OSTX trades on the NYSE exchange and files with the SEC under CIK 1795091. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate OSTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for OS Therapies Inc directly from SEC EDGAR.
Net Income
Q1 2026
$-10.4M
Free Cash Flow
Q1 2026
$-4.6M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
-269.0% YoYOperating Income
-561.0% YoYEPS (Diluted)
+32.9% YoYTotal Assets
+757.0% YoYOp. Cash Flow
-373.5% YoY| Metric | FY 2025 | FY 2023 | FY 2022 |
|---|---|---|---|
| Net Income | $-28.8M -269.0% | $-7.8M | — |
| Operating Income | $-28.7M -561.0% | $-4.3M | — |
| EPS (Diluted) | $-0.98 +32.9% | $-1.46 | — |
| Total Assets | $6.8M +757.0% | $798.1K | — |
| Operating Cash Flow | $-14.2M -373.5% | $-3.0M | — |
AI Insight: OSTX Financial Trends
OS Therapies is a pre-revenue biotech burning cash at an accelerating rate, with net losses deepening to $10M in Q1 2026.
• Net income loss widened from $2M in Q2 2024 to $10M in Q1 2026, reflecting intensifying R&D spend without offsetting revenue.
• Operating cash burn peaked at $5M in Q3 2025, stabilizing at $5M in Q1 2026 despite worsening operating losses.
• Equity swung negative to $11M deficit in Q1 2026 from negative $27M in Q2 2024, showing deteriorating book value.
⚠ Zero debt provides runway flexibility, but absence of revenue combined with $10M quarterly burns suggests finite cash reserves.
⚠ Q4 2025 marked the steepest net loss ($13M) on record; watch for inflection to positive cash generation or a funding event.
AI Insight: OSTX Ratio Trends
Insufficient data to assess operational trends; only leverage metrics visible across sparse quarters.
• Debt-to-equity remained minimal at 0.02–0.03 across Q2 2025 and Q3 2025, indicating conservative balance sheet.
⚠ Operating margin, net profit margin, ROE, ROA, and ROIC all absent from Q2 2024 through Q1 2026; cannot assess profitability or capital efficiency trends.
Get alerted when OSTX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for OS Therapies Inc including:
Top Institutional Holders of OSTX
VANGUARD CAPITAL MANAGEMENT LLC
$661.9K469,467 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$632.7K448,737 shCM Management, LLC
$564.0K400,000 shUBS Group AG
$491.6K348,678 shGEODE CAPITAL MANAGEMENT, LLC
$394.9K280,045 shHOWARD FINANCIAL SERVICES, LTD.
$346.1K245,436 shVANGUARD FIDUCIARY TRUST CO
$164.5K116,663 shSTATE STREET CORP
$128.6K91,200 shNORTHERN TRUST CORP
$93.1K66,054 shBlackRock, Inc.
$91.3K64,772 sh
| Fund | Value | Shares |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $661.9K | 469,467 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $632.7K | 448,737 |
| CM Management, LLC | $564.0K | 400,000 |
| UBS Group AG | $491.6K | 348,678 |
| GEODE CAPITAL MANAGEMENT, LLC | $394.9K | 280,045 |
| HOWARD FINANCIAL SERVICES, LTD. | $346.1K | 245,436 |
| VANGUARD FIDUCIARY TRUST CO | $164.5K | 116,663 |
| STATE STREET CORP | $128.6K | 91,200 |
| NORTHERN TRUST CORP | $93.1K | 66,054 |
| BlackRock, Inc. | $91.3K | 64,772 |
More Healthcare Companies
View all Healthcare →Put OSTX on your watchlist
Track score changes the day OS Therapies Inc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is OSTX a good stock to buy?
13F Pro's AI-powered analysis of OS Therapies Inc (OSTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for OSTX are available on the OSTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own OSTX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling OSTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of OS Therapies Inc's investment landscape.